Skip Navigation


JAC Advance Access originally published online on February 28, 2008
Journal of Antimicrobial Chemotherapy 2008 61(5):1048-1052; doi:10.1093/jac/dkn067
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/5/1048    most recent
dkn067v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Papp, E.
Right arrow Articles by Côté, H. C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Papp, E.
Right arrow Articles by Côté, H. C. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Longitudinal effects of thymidine analogues on mtDNA, mtRNA and multidrug resistance (MDR-1) induction in cultured cells

Eszter Papp, Izabella Gadawski and Hélène C. F. Côté*

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada

Received 23 November 2007; returned 20 January 2008; revised 24 January 2008; accepted 26 January 2008


* Corresponding author. Tel: +1-604-822-9777; Fax: +1-604-822-7635; E-mail: helene.cote{at}ubc.ca

Objectives: HIV nucleoside reverse transcriptase inhibitors (NRTIs) can cause mitochondrial toxicity. In spite of several studies performed on cells, little is known about their long-term effects on mitochondrial DNA (mtDNA), mitochondrial gene expression (mtRNA) and cellular protective mechanisms that such exposure may trigger. Our aim was to investigate the longitudinal effects of two thymidine analogue NRTIs, zidovudine and stavudine, on human cells, measuring their effects on the levels of mtDNA, mtRNA and on induction of the multidrug resistance (MDR) gene MDR-1.

Methods: K562 lymphoblastoid cells were treated for 74 days with zidovudine or stavudine concentrations corresponding to ~1x, 20x and 400x those measured in plasma. Samples were collected longitudinally and assayed for mtDNA, mtRNA and MDR-1 mRNA levels by real-time quantitative PCR. mtDNA deletions were investigated by long PCR.

Results: Upon exposure to both zidovudine and stavudine, an early dose-dependent and transient increase in mtDNA content was observed. This was followed by a concurrent and transient elevation in both mtRNA and MDR-1 mRNA levels. Interestingly, the increase in mtRNA was most pronounced at low concentrations, whereas that of MDR-1 expression occurred at the highest concentrations only. No mtDNA deletions were detected under any conditions.

Conclusions: Cellular response to thymidine analogue NRTI exposure showed a complex, time- and dose-dependent pattern over time. We report for the first time that NRTIs can induce MDR-1 expression; however, this effect is delayed, possibly in response to oxidative damage or mitochondrial dysfunction. Our results indicate that longitudinal experiments may refine our knowledge about NRTI toxicity.

Keywords: stavudine , zidovudine , toxicity , in vitro , lymphoblastoid cells , long-term


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.